Disease Areas
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.